metastatic castrate-resistant prostate cancer | sciencenewsnet.in

Breaking News

Structural Safety Monitoring of Buildings with Color Variations

Out of Africa: UT Southwestern cardiologist gets to the heart of Zambia’s No. 1 health threat

Weight loss interventions associated with improvements in several symptoms of PCOS

Policies assuring safe practice by late-career physicians vary widely among health care organizations

Researchers report first published case of a patient with treatment-emergent neuroendocrine prostate cancer who showed a remarkable response to an anti-HER2 antibody-drug conjugate

Patients outside metropolitan areas often travel significantly more than 20 minutes for primary care visit

Discovery of a protein’s key role in RNA processes could improve disease treatment in humans and plants

Health Research Launches Into Orbit to Discover How Spaceflight Affects Blood

Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University

Gastrointestinal Surgeon Fabrizio Michelassi, MD, FACS, Elected Chair of ACS Board of Regents

05 Nov, 2024

Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer

March 2, 2023 sarah JonasResearch Results

A combination treatment that targets the immune system helps treat aggressive prostate cancers that don’t respond to conventional therapies.

Researchers uncover a way to harness the power of immunotherapy for advanced prostate cancer

August 2, 2021 sarah JonasResearch Results

Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.

BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs

June 18, 2021 sarah JonasResearch Results

In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.